FastTrack CPD - ADHD guidelines for Australian general practitioners
Overview
The Australian Clinical Practice Guideline for ADHD provides evidence-based recommendations for diagnosing, managing, and supporting individuals with ADHD, tailored to the Australian context. Developed by the Australasian ADHD Professionals Association (AADPA), the guideline emphasises person-centred, multidisciplinary approaches to improve quality of life for the over one million Australians affected.
Identification and diagnosis
Universal screening for ADHD is not recommended. However, clinicians should remain vigilant for ADHD in populations with a high prevalence which include individuals with a history of ADHD in immediate relatives, those with neurodevelopmental conditions, or those in correctional facilities (see Guideline for full list).
It is important to be aware that ADHD is often under-recognised in females.
Diagnosis requires a comprehensive assessment, incorporating clinical and psychosocial assessment, developmental and medical history, observer reports, and the use of validated criteria (DSM-5, ICD-10/11) by an appropriately trained clinician. Comorbid conditions, such as anxiety or substance use disorders, should be carefully evaluated.
Treatment
A multimodal treatment approach is advised:
-
Non-pharmacological interventions:
-
parent/family training: to equip parents/carers with the specific skills required to meet the additional needs of children and adolescents with ADHD
-
cognitive-behavioural interventions: include a variety of approaches that aim to address behavioural factors, psychological distress, and mental ill-health, rather than ADHD symptoms
-
lifestyle modifications: with a specific focus on optimising sleep, diet, and physical activity to improve day-to-day functioning
-
ADHD coaching: to improve executive functioning, symptoms, self-esteem, general wellbeing, and overall quality of life
-
Pharmacological treatment:
-
pharmacological treatment for children ≤5 should involve a clinician with experience in child development and ADHD
-
first-line medications include monotherapy with stimulants (methylphenidate, dexamfetamine, lisdexamfetamine) for children >5 years old, adolescents, and adults, where symptoms are causing significant impairment
-
non-stimulant alternatives such as atomoxetine or guanfacine may be used if stimulants are ineffective or contraindicated
-
comprehensive monitoring of medication effects include height/weight, cardiovascular function, sleep, sexual function, seizures, emotional and mental health
-
medication should be initiated and monitored by appropriately trained clinicians
Implementation
Practitioners are encouraged to adopt the guideline’s recommendations collaboratively with patients and their carers, integrating evidence, clinical judgement, and individual preferences. Consistent monitoring and adjustment of treatment plans ensure optimised outcomes.
Related Courses
With increasing public awareness of ADHD, GPs are now at the front line of identifying and supporting management of this condition. Up to 10% of children and 5% of adults exhibit ADHD symptoms, indicating there is a heightened need for GPs to understand their role in supporting these patients.
Become a member and get unlimited access to 100s of hours of premium education.
Learn moreDiagnosing early Parkinson’s disease is no easy task. Managing it effectively can be even more difficult. In this quick activity, you will refresh your knowledge on the diagnosis of Parkinson’s disease including crucial red flags, and advance your understanding of both pharmacological and non-drug interventions, while earning CPD points.
Understand the requirements of the updated RACGP recommendations for the Doctor’s Bag to stay compliant and prepared for your next clinical emergency
A renewed partnership between Medcast and RACGP will ensure RACGP members have privileged access to discounted Basic Life Support training. The online course, meticulously aligned with guidelines, enables GPs to fulfil mandatory CPR course requirements.